Evotec AG (NASDAQ:EVO) Receives $7.00 Average PT from Brokerages

Evotec AG (NASDAQ:EVO) has been given a consensus recommendation of “Hold” by the five analysts that are presently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating on the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $7.00.

Several research firms have recently commented on EVO. Berenberg Bank initiated coverage on Evotec in a research report on Tuesday. They issued a “buy” rating for the company. Wall Street Zen upgraded Evotec from a “sell” rating to a “hold” rating in a research note on Saturday, January 10th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Evotec in a research report on Monday, December 29th.

Evotec Stock Performance

Shares of NASDAQ:EVO opened at $3.52 on Tuesday. The firm has a 50 day moving average of $3.34 and a 200 day moving average of $3.55. The company has a debt-to-equity ratio of 0.48, a current ratio of 2.12 and a quick ratio of 2.03. Evotec has a 52 week low of $2.84 and a 52 week high of $4.80.

Institutional Investors Weigh In On Evotec

Several institutional investors have recently bought and sold shares of the company. Valeo Financial Advisors LLC acquired a new position in shares of Evotec in the 2nd quarter valued at $43,000. BNP Paribas Financial Markets grew its stake in Evotec by 62.2% during the 2nd quarter. BNP Paribas Financial Markets now owns 12,000 shares of the company’s stock valued at $50,000 after purchasing an additional 4,600 shares during the last quarter. Thrivent Financial for Lutherans acquired a new position in shares of Evotec in the third quarter valued at about $53,000. Bank of America Corp DE raised its stake in shares of Evotec by 262.5% in the fourth quarter. Bank of America Corp DE now owns 12,828 shares of the company’s stock worth $53,000 after purchasing an additional 9,289 shares during the last quarter. Finally, XTX Topco Ltd acquired a new stake in shares of Evotec during the second quarter worth about $66,000. 5.81% of the stock is currently owned by institutional investors and hedge funds.

About Evotec

Evotec SE (NASDAQ:EVO) is a global biotechnology company headquartered in Hamburg, Germany, specializing in drug discovery and development partnerships. The company leverages its integrated discovery platforms to support pharmaceutical and biotech clients in advancing novel therapies from target identification through preclinical development.

Evotec’s service offering encompasses high-throughput screening, bioanalytics, combinatorial chemistry, structural biology, pharmacology, and computational drug design.